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Background: South Africa has a high and rising prevalence of hypertension. Many affected individuals are not
using medication, and few have controlled blood pressure. Until recently, primary care clinics focused on maternal
and child health and management of acute conditions, but new government initiatives have shifted the focus to
chronic diseases, including HIV/AIDS and hypertension.
Methods/Design: The Nkateko trial will test the effectiveness of clinic-based lay health workers (LHWs) in supporting
hypertension management. It is a pragmatic, cluster randomised controlled trial based in the Agincourt subdistrict of
northeast South Africa, and it is underpinned by long-term health and demographic surveillance. Eight primary care
facilities, with their catchment communities, are randomised to usual care or the addition of LHWs focused on chronic
care. All clinics (intervention and control) will be provided with a clerk to collect information on clinic attendees and
will match them to preexisting surveillance records. Intervention clinics will have LHWs working alongside nursing staff
and focusing on health care for people with chronic conditions, particularly hypertension. The LHWs will be supported
by an implementation manager, who will work with clinic staff to develop the most effective role for the LHWs. Control
clinics will continue to provide usual care. The primary outcome will be the change between two population surveys
conducted before and after the intervention in the proportion of the population with uncontrolled hypertension and a
risk profile indicating at least moderate risk of cardiovascular disease. A process evaluation will be based on a realist
approach using patient exit interviews, clinic observations and interviews with health professionals, LHWs and patients
to document the intervention and its implementation.
Discussion: There are challenges in the design of this trial. Assessing change through population surveys may reduce
measurable effects; however, we feel this is appropriate because we aim to attract those who currently do not use
clinics, and we hope to improve care for clinic users. Clinics were randomised at an open meeting because we were
concerned that a remote process of randomisation would not be trusted by the community. We are constantly
working to achieve an effective balance between the intervention and process evaluations.
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There is a complex epidemiological and demographic
transition underway in sub-Saharan Africa. The HIV/
AIDS epidemic, which has affected a large proportion of
the population and caused a dramatic decrease in life
expectancy, coexists with an ageing population and an
increase in the prevalence of noncommunicable diseases.
It is expected that the proportion of the population
60 years of age and older will increase almost threefold by
2025 compared to 1985 data [1]. At the same time, partly
due to this demographic shift, South Africa has a high and
rising prevalence of hypertension [2,3]. Hypertension
currently affects around 40% of the adult population in
the Agincourt subdistrict, a rural area covered by the
Agincourt Health and Demographic Surveillance System
(HDSS) (unpublished data; Clark S, Gómez Olivé FX see
also [4]. In low-resource rural settings, fewer than half of
individuals affected by hypertension are aware that
they have hypertension, and fewer than 10% achieve
appropriate blood pressure levels [5]. There is marked
variation in the management of hypertension and other
chronic diseases, owing to poor functioning of primary care
services, which have historically been focused on maternal
and child health and the management of acute illness rather
than chronic conditions. Adherence to medication is
suboptimal; long-term patient retention is low; and
little attention is paid to potential comorbidities [1].
South Africa also has the highest prevalence of
HIV/AIDS in the world [6]. The country’s antiretroviral
treatment programme is the largest worldwide, and it has
seen recent notable increases in coverage [7]. Substantial
knowledge has been generated on adherence support,
tracing defaulters and enabling patient participation
through treatment literacy and patient support groups
[8]. This knowledge and experience may potentially
be transferable to the management of hypertension,
for which the same type of health care intervention may
be equally effective in addressing the escalating burden.
Treatment of HIV and tuberculosis relies heavily on lay
health workers to support patient adherence. In South
Africa, lay health workers have successfully (1) provided
pre- and posttesting and adherence counselling, (2) assisted
patients in navigating their engagement with health staff
and (3) helped in tracing defaulters [9-12].
The development of this trial has been informed by
the experience of the antiretroviral service and guided
by the Wagner conceptual framework for chronic
disease care, which emphasise the need for productive
interactions between patients, providers and the broader
health system [13]. Effective chronic disease care requires
a reliable drug supply, longitudinal patient records to
monitor care over time and adequately staffed clinics. It is
also important that patients have sufficient self-efficacy
to manage their illness with support from their socialnetwork. In an area such as the Agincourt subdistrict,
where more than 90% of all adults have access to a mobile
phone, text messaging could be used to improve medica-
tion adherence and health-related behaviour modification.
There is evidence from a systematic review that text
messaging was well accepted and showed early efficacy in
most studies by improving medication adherence and
health-related behaviour modification [14].
A recent national Department of Health initiative
has sought to implement an integrated chronic disease
management (ICDM) programme in 50 selected clinics in
3 provinces [15]. The aim of the ICDM programme is to
strengthen chronic care by providing additional nurse
training, equipment audit and replacement, improved
drug supply, reorganised patient flow to allow separate
management of chronic diseases and reduction of waiting
times, advanced booking, and prepacked medication. The
ICDM programme is already operational to a varying
extent in the eight clinics in which this trial is being
implemented.
Process evaluations are an important addition to
randomised trials; they allow better understanding of
the causal processes which may facilitate or obstruct
change and help to inform the interpretation of out-
comes [16,17]. This is particularly important in a
complex trial such as this one, where the interaction
between the lay health workers, health care profes-
sionals, patients and the wider community is likely to
be many-layered and where the interaction between
the communities and the primary care clinics that
serve them is poorly understood.
Methods/Design
The full version of the study protocol is available at
http://www.chp.ac.za/research/Nkateko/Pages/default.aspx.
Research hypothesis and objectives
The hypothesis is that the introduction of lay health
workers to assist nurses with the management of patients
with chronic diseases in rural primary care clinics will
improve population-level management of hypertension by
improving diagnosis, retention in care and adherence to
treatment by individuals with hypertension.
The following are our research objectives:
1. To compare the effectiveness of clinic-based lay health
workers to ‘usual care’ in improving the management
of hypertension (including access to care, adherence
to treatment, and management) in rural South Africa
2. To conduct a realist evaluation to understand the
patient, intervention, implementation, health care
system and community barriers and facilitators that
explain patient outcomes in the intervention and
‘usual care’ clinics
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strengthen policy and practice in similar rural
settings of South Africa and southern Africa.
Study design
The Nkateko trial is a cluster randomised controlled trial
comprising eight clusters each of which consists of a
primary health care facility and the community it
serves, including residents in a defined catchment
area within the Agincourt subdistrict. Figure 1 shows
a schematic representation of the trial.
In the trial, we are testing a health service intervention
which involves placing lay health workers in four inter-
vention clinics. The lay health workers will assist
clinic nurses with the management of patients with
chronic diseases. The outcome of the study will be
evaluated by using two population-based, random
sample, cross-sectional surveys, one at baseline and
one at the conclusion of the intervention.
The study has been approved by the Committee for
Research on Human Subjects (Medical), the University
of the Witwatersrand (reference M130347, M130754,
M130964), the Biomedical Research Ethics Committee at
the University of Warwick (reference REGO-2013-062,
REGO-2013-203, REGO-2013-562) and the Mpumalanga
Province Research and Ethics Committee (dates of letters:
7 June 2013, 18 September 2013, 6 November 2013). This
cluster randomised trial is a type A trial as defined in the
2002 Medical Research Council (MRC) document on
cluster randomised trials [18]. The decision to consent to
organisational change in a clinic cannot depend on the
consent of users of the clinic. Consent has been obtained
from the national, provincial and district authorities, and
discussion of implementation within each clinic has taken
place in partnership with the clinic staff. We have put
notices in all clinics explaining that the clinic is being
observed. Individual informed consent is obtained fromFigure 1 Design of the Nkateko trial. HDSS, Agincourt Health and
Demographic Surveillance System; LHW, Lay health worker.each participant who is individually approached. This
includes all clinic patients who allow their clinical
data to be collected and linked to their existing
demographic surveillance data, all participants in the
two cross-sectional surveys, everyone (health service staff,
research staff and community members) who engage in
an interview or authorise a consultation to be observed,
and all patients completing an exit questionnaire when
they leave a clinic.
Preintervention preparation
First steps in developing plans for the intervention were to
carry out literature searches for similar interventions and to
meet with local and provincial health service personnel. We
then performed a situation analysis in all the local clinics.
This involved interviews with clinic staff and collecting and
analysing retrospective data on the appointments system
and attendance of patients with chronic diseases. We also
deployed local trained field workers to conduct nonpartici-
pant observations over a period of 3 days in each clinic. We
also held meetings with provincial and district stakeholders
and workshops with staff in each clinic to feed back
the results of our preparatory work to discuss how
the interventions might proceed.
Study site
The trial is based in the Agincourt subdistrict of
Mpumalanga Province, South Africa. This rural area
is a former Bantustan, with limited resources, high levels
of unemployment and high levels of labour migration
[19,20]. In a population-based survey of 3,729 adults older
than 15 years of age in 2010, the prevalence of hyperten-
sion was found to be 40% in women and 39% in men, and
the prevalence of HIV was 27% in women and 19% in
men (unpublished data). There are seven publically
funded clinics and one health care centre at the site, plus
two clinics just over the border. For this trial, one clinic
from the border area, together with the population it
serves (a population partly in the HDSS area), will be
included as a pilot clinic. The other border clinic will not
be considered further. The eight facilities within the site,
and with their associated communities, will comprise
the clusters. Until recently none of the health facilities
kept individual longitudinal patient records. Moreover,
individuals are free to use any clinic that is convenient,
so, although each clinic has its own catchment area, it is
not possible to define a ‘clinic user’ population for each
clinic a priori.
Since 1992, the MRC/Wits Agincourt Research Unit has
collected population data, and vital events (pregnancy
outcome, death, migration) are updated yearly [19]. For
the purpose of this study, the total population under
surveillance is about 90,000 people (52,592 older than
18 years of age) who live in 15,500 households in 26
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the planned population surveys and also make it possible
to trace patterns of clinic use by identifying clinic users at
the facility levels and linking them to the population
database. Moreover, the MRC/Wits Agincourt Research
Unit provides an administrative research structure to
support the trial.
Intervention and control arms
All eight clinics will continue to implement the govern-
ment’s ICDM strategy by providing separate care for
patients with chronic diseases. In addition, as part of the
trial, all clinics will have an attached data clerk responsible
for collecting identifiers of all consenting attendees of the
chronic disease clinic to allow their identification in the
MRC/Wits Agincourt surveillance database. The linked
data will enable us to understand patterns of clinic use
which may not be geographically determined, as well as
differential clinic use associated with sex, age and relative
household wealth of clinic users. They will also allow us to
monitor whether patterns of clinic use change over the
15 months of the intervention. Previous research [21] has
confirmed the key identifiers for posterior links with the
census are name, surname, age or date of birth, sex, village
of residence, cell phone number, national ID number and
name of another person living in the household. The
system was piloted successfully in two clinics in 2013
in preparation for the Nkateko trial.
Intervention clinics will also be provided with two
full-time lay health workers for 15 months to assist in
the management of the patients with chronic diseases,
particularly patients with hypertension. Building on
experience with lay counsellors in antiretroviral therapy
delivery [9], we expect that the lay health workers will
provide adherence counselling; help to improve treatment
literacy; use text messaging, telephone or personal
contacts to remind patients of appointments [22]; and
assist with filing of patient records and prepacking of
medications. However, the exact roles of the lay
health workers will be decided on a clinic-by-clinic basis in
workshops run with the clinic staff by the implementation
manager, with modification of noncore components to
encourage local ownership. Core nonmodifiable components
include appropriate staff selection, preservice and in-serviceTable 1 Modified South African Guideline: stratification of ca
Presence of risk factors or other
Blood pressure (mmHg) No risk factors One
risk f
SBP 140 to 159 or DBP 90 to 99 Low added risk Mode
SBP 160 to 179 or DBP 100 to 109 Moderate added risk Mode
SBP 180+ or DBP 110+ High added risk Very
aDBP, Diastolic blood pressure; SBP, Systolic blood pressure. Hypertension is definedtraining, and staff and programme evaluation. A local
experienced nurse has been appointed as the imple-
mentation manager who will oversee the selection, intro-
duction and functioning of the lay health workers. We
believe this mirrors the type of structure that might be
used by a provincial or district health department
when introducing such an initiative. The implementation
manager is responsible for the development of a functional
relationship between the lay health workers and clinic staff,
as well as the performance management and evaluation of
the lay health workers.
Study outcomes
We aim to improve the management of hypertension
with the goal of achieving a reduction in the proportion of
the population with uncontrolled hypertension and a risk
profile indicating at least moderate risk of cardiovascular
disease. To do this, we aim to both increase the number of
people receiving active management of their hypertension
and improve the management of blood pressure in those
patients already in active management. Because we
hope to reach people not currently using the clinics,
we have chosen to measure the outcome of the trial
at the population level with the use of two population
surveys (before and after the intervention).
The primary outcome we will measure is the difference
in the change in intervention and control clinics between
the two surveys in the proportion of the population who
have uncontrolled hypertension and a risk profile indicating
at least moderate risk of cardiovascular disease. The
definition of this risk profile is shown in Table 1. It
reflects the concepts in the 2011 South African guidelines
[23], which call for a focus on people at moderate or
greater cardiovascular risk. Although the guidelines require
clinical diagnoses, we are limited by what is possible in a
population survey, so, for the purposes of this trial, we will
define the cardiovascular risk factors and associated clinical
conditions as outlined in Table 2.
The secondary outcomes of the trial are shown in
Table 3.
Power calculations, sample size and randomisation
In the absence of relevant data, we made the assumption








rate added risk High added risk Very high added risk
rate added risk High added risk Very high added risk
high added risk Very high added risk Very high added risk
as SBP >139 mmHg or DBP >89 mmHg.
Table 2 Risk factors and associated clinical conditions
used for definitions of ‘increased cardiovascular risk
associated with hypertension’ in the Nkateko triala
Risk factors Associated clinical
conditions
Sex/age: men >55 yr, women >65 yr Self-reported coronary heart
disease
Smoking at least every day Self-reported heart failure
Dyslipidaemia TC >5 mmol/l Self-reported stroke or TIA
Family history of CVD (sex/age):
men <55 yr, women <65 yr
Waist circumference: men >94 cm,
women >80 cm
aCVD, Cardiovascular disease; TIA, Transient ischaemic attack. TC.
total cholesterol.
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4,000 participants from among a sample of 5,000, based on
an estimated 80% response, and will give us approximately
500 people in each clinic (cluster). We adopted the use of
the coefficient of variation as employed in similar study
settings when a good intracluster variation is not available
[24-26]. Data collected in Agincourt in 2010 provided a
prevalence of moderate or greater cardiovascular risk of
36% and a coefficient of variation of 0.132 (error margin,
4.5% (0.132 ± 0.045)). Using these data, we calculated that
we will have 88% power to detect a difference between
an unchanged prevalence of risk of 36% in the control arm
and a reduction to a prevalence of risk of 25% in the inter-
vention arm. These calculations assume that the coefficient
of variation will be similar in the two groups and that
effects of the interventions are similar across clusters.
For each of the two population surveys, we will select
a random sample of 5,000 people older than 18 years of
age from the demographic surveillance database. The
samples for the two surveys will be disproportionately
stratified to ensure adequate representation of men and
older people. This is necessary because (1) the populationTable 3 Secondary outcomes
Source Outcome








clinic in the p
Clinic link with census records Difference in
to prescribed
Difference in
proportion ofpyramid is heavily weighted toward younger people, and
(2) there are fewer men than women amongst older adults
due to labour migration [20] and the longer survival of
women. Each sample will be independently selected, but
we expect some overlap (estimated at around 4 to 500
individuals) between the two samples. All the individuals
selected in both samples will be identifiable.
Randomisation of the eight clinics has been carried
out at a public meeting attended by 38 members of the
community, including clinic staff, lay members of clinic
committees and members of a community advisory group.
This was done to ensure that the community understands
the purpose of the trial and that the clinic staff and wider
community are confident that the randomisation was truly
random. Eight pieces of paper with the names of the
clinics were shown to attendees at the meeting, then put
into sealed envelopes that were put in a box, which was
shaken repeatedly before each envelope was chosen. The
first clinic chosen was an intervention clinic, the second a
control clinic and so forth.
Baseline and end-of-intervention population surveys
All consenting participants in the surveys will have their
blood pressure measured by trained field staff three times
using an Omron automatic blood pressure machine
(model M6W; Omron Healthcare, Lake Forest, IL, USA).
The questionnaire takes around 30 minutes to administer,
thus allowing both surveys to be completed within a
12-week period before the start of the intervention
and at the end. Information will be collected regarding
respondents’ use of primary care clinics in the past
12 months and their preferred clinic. Information on
factors related to cardiovascular risk will be collected, and
respondents will also be asked if they have had their blood
pressure checked by a doctor or nurse in the past
year, if they have ever been told they have hypertension
and if they are using medication for hypertension (see
Additional file 1 for a copy of the questionnaire).change in proportion of the population with undiagnosed hypertension.
change in the proportion of the population reporting they had had their
e measured.
change in the proportion of the population reporting they are using
r hypertension.
changes in the proportion of the population at different levels of blood
ed cardiovascular risk by age group and sex.
change in the proportion of the population reporting they attended a
ast year.
proportion of population with diagnosed hypertension who are adherent
medication, defined by recorded collection of prescriptions.
retention in care of people with diagnosed hypertension defined by the
appointments kept during the study period.
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Quantitative data will be entered at the field site using
double data entry. Personal identifiers will be encrypted
once the data have been entered and cleaned. Encryption
codes will be held securely in the MRC/Wits Agincourt
Research Unit under the guardianship of the data manager.
After completion of data collection, cleaning and encryp-
tion, the data files will be placed with other legacy data on
the data warehouse server at the Agincourt research site.
All data sets derived from this project will be made pub-
licly available within 1 year of the completion of data collec-
tion and cleaning. Secondary data users will submit a
request for data access to the data custodians, appointed by
the project principal investigators, by completing an online
form. If the request falls within the bounds of appropriate
data access requests as specified in the ‘MRC principles for
access to, and use of, MRC funded research data’, then it will
be approved. Collaboration with the original investigators in
resulting publications will be encouraged.
A full analysis plan will be agreed upon with the
management team and the trial steering committee
before the analyses are begun. The primary analysis
will be on intention to treat and will be carried out
using STATA 13 software (College Station, TX, USA).
Up to this point, clinic identifiers will be encrypted
so that the primary analysis is carried out in blinded
fashion regarding which clinics are the intervention
clinics. In descriptive analyses, frequency distributions
of categorical variables and summary measures of
continuous variables will be reported. Baseline values in
the intervention and usual care arms will be described.
To allow for confounding, the two-stage regression
model will be used for analysis of the binary primary out-
come ([27], pages 163–198). First, two logistic regression
models for control and intervention clusters that include
covariates will be fitted separately. Covariates in the two
models will both be cluster-level factors (for example, clinic
size) and aggregated individual-level factors (for example,
sex and age). Second, observed and fitted values for each
cluster will be compared by computing residuals. We ex-
pect relatively few missing values, especially for individual
demographic data, because this trial is taking place in an
established HDSS site with a rigorous quality assurance
system.
Objectives and approach of the process evaluation
Given the importance of context, process and actors in
the performance of the health care system [28], we cannot
assume that the results of a health services randomised
controlled trial will be transferable to other health
care settings. We are therefore undertaking an extensive
process evaluation and adopting a critical realism approach
in which the predominant question is, what works for
whom under what conditions? This approach acknowledgesthat preexisting health care system structures and processes
affect, and are affected by, the intervention actors. In this
evaluation, we aim to understand the causal processes
of change. We will take a realist approach in the
evaluation and explore the ‘mechanism’ by which the
intervention has its effect [29]. The following are the
objectives of the process evaluation:
1. To examine how different aspects of the
intervention function in the different clinics and the
mechanisms by which the intervention affected or
failed to affect the primary outcome
2. To examine the extent to which the lay health
workers and other clinic staff were able to work
within the context of the complex adapting system
of a primary health care facility, by learning,
interacting and self-organising to establish sustained
improvements in care
3. To explain how the implementation processes
shaped the intervention and its functioning
4. To explain the role of the local context in
determining outcomes
Data collection and analysis for the process evaluation
In the study, we will use a range of qualitative methods,
including interviews and observation. As is standard in
qualitative methods, sampling will be purposive, designed
to ensure representation of a range of views and inputs.
Each clinic and its attending population will be treated as
a single case, and a case study approach will be used to
compare and contrast experiences in the four intervention
clinics. Combining qualitative and quantitative data will
allow the development of within- and across-clinic analyses
to explain and interpret outcomes.
Data on the clinic use of individuals will be collected
through a linkage system, where consenting patients’
clinical details will be linked to the demographic surveil-
lance system. In addition, we will collect a range of quanti-
tative and qualitative data for the process evaluation.
Quantitative data will include brief exit interviews with
patients who have attended the chronic disease clinic and
have a diagnosis of hypertension. We will ask whether
they had their blood pressure measured, what advice they
were given, whether they have been given any medication
and whether a return visit has been booked. Nursing
staff in the clinics will be asked to complete a structured
questionnaire on their motivation.
Qualitative data will include nonparticipant observation
and repeated interviews with trial employees and health
service staff, including clinic supervisors and subdistrict
staff. Three purposively selected groups of people in the
community will be followed up with in-depth interviews.
There will be three observation visits to each clinic over the
period of the intervention to observe the operation of the
Thorogood et al. Trials 2014, 15:435 Page 7 of 9
http://www.trialsjournal.com/content/15/1/435intervention activities, to describe patient pathways and to
describe the health care system facilitators and barriers to
hypertension care. Throughout the period of the interven-
tion, the lay health workers and implementation manager
will be interviewed monthly to capture information on the
functioning of the intervention; the usefulness of the inter-
vention activities; adaptations to the context, barriers and
facilitators to care; the relationship between the various
actors; and other changes taking place in the clinic.
Three cohorts of community members will be purpos-
ively identified for two in-depth interviews at around 3 to
5 months after the initiation of the trial and again at around
12 to 15 months. The first cohort will comprise both
patients who only intermittently adhere to their medication
and patients who have a high level of adherence. The
second cohort will comprise individuals who report that
they normally attend one of the clinics in the control arm
of the study and report, when interviewed, that they have
hypertension. The third cohort will include individuals with
raised blood pressure upon measurement who either do
not report that they have hypertension or who know their
diagnosis but are not taking treatment, which maybe
because they are not adherent to prescribed treatment or
because they have not been prescribed any treatment.
Economic evaluation
A partial economic evaluation will be undertaken
alongside the trial. As there is potential for multiple
key outcomes that cannot be aggregated into a single
outcome, a cost–consequence analysis will be the primary
economic study undertaken to obtain an array of output
measures alongside the costs. This will enable us to show
the trade-offs associated with each scenario. We will
collect patient-level costing data to examine the cost
implication for the public sector as the funder of primary
health care, as well as costs to the patient of participating
in the intervention. Salary and training costs for the
lay health workers and experienced nurse, as well as
communication costs (such as telephone calls, SMS)
will be included in the intervention cost, as well as
the cost of additional services delivered by the health
facility. Costs associated with the government’s ICDM
programme, which is common across both intervention
and comparator sites, will not be included in the analysis.
Costs (in South African rand) will be collected over the
course of the study, and all prices will be inflation-adjusted
to the final year of the study. Nonparametric bootstrapping
will be used to assess the effect of variation in patient-level
outcomes on the costing results.
Discussion
We have faced a number of challenges in designing this
trial. We already knew that at least half of the people
with hypertension were not aware of their condition andtherefore were not receiving regular treatment [30], and
we wanted to target those people as well as the people
already in the clinic system. Also, until very recently, no
clinic records of individual patients were kept, and the
new recordkeeping system was of variable quality. It was
apparent, therefore, that a simple clinic record–based
measure would not be possible as the primary outcome. We
therefore decided to use baseline and end-of-intervention
population surveys to measure change. This created a
further challenge of carrying out a large-enough survey to
achieve adequate power quickly enough to obtain a realistic
baseline measure.
Because the intervention involved extra resources for
some clinics, we were concerned that the process of
randomising the clinics could lead to suspicion about
whether it was truly random and thereby create negative
feelings. We therefore held a public meeting at which the
randomisation took place.
To ensure that the intervention achieves the best possible
outcome, the implementation manager will aim to increase
clinic staff ’s awareness of patient constraints, adapt activ-
ities to suit the local context and obtain local commitment.
This engagement may change the local clinic context, and
context and intervention are likely to coevolve. As a result,
it is not realistic to attempt to maintain rigid adherence to
a predetermined protocol. It is therefore important to
document the evolution of the intervention, which is the
reason for the extensive process evaluation. At the same
time, however, to maximise the external validity of the
study, it is important to keep the intervention realistically
close to the type of intervention that might be feasible in a
low- or middle-income country. This has led to two
important dilemmas for the team. First is the extent to
which findings from the process evaluation should be fed
back to the implementation manager and lay health
workers, as standard government policy implementation
does not receive the benefit of ‘real-time’ evaluation to
enable improvement. Second is the extent to which the trial
team should intervene to provide extra resources where the
lack of resources is preventing the effective functioning of
the lay health workers. In regard to both of these dilemmas,
we are regularly making day-to-day decisions, balancing the
need for external validity with the practicalities of getting
an intervention to run in a challenging environment. All
these decisions are being carefully recorded so that we can
provide a fully informed report at the end of the trial.
Trial status
Because of the design of the trial, it is difficult to define
the status of recruitment. There are eight clinics, four of
which receive the intervention and four which do not.
They have been randomised, and the lay health workers
have been in place since February to March 2014. Although
the unit of randomisation is a clinic, the participants could
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the clinics. They are participating or declining to participate
by consenting to their data being linked to census data and
by consenting to complete an exit questionnaire or permit
their consultation to be observed as they attend the clinics.
In that sense, we are just over halfway through recruitment
(10 months of an 18-month period). The outcome is
measured by population surveys at baseline and at
the end of the intervention. If the people in those
surveys are considered to be the participants, then we
have recruited half (one survey). A separate group of
around the same number of people will be asked to
complete the survey at the end. The trial status was
most recently updated 6 November 2014.
Additional file
Additional file 1: Questionnaire to be used in two population surveys.
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